Our data of ANGPTL3 inhibition with evinacumab evoke previous observations in patient populations where LOF mutations in ANGPTL3 led to pan-hypolipidemia.26–28 Results from the single ascending dose study of evinacumab treatment of patients with severe hypertriglyceridemia and LPL pathway mutations are being reported in a separate publication. The gene discussed is LPL; the disease is hypertriglyceridemia.